3D Mol Similar

17-Methyltestosterone

: Iupac Name：(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; CAS No.: 58-18-4; Molecular Weight：302.45; Modify Date.: 2022-10-31 05:56; Introduction: Methyltestosterone is a synthetic analog of testosterone that possesses all of the properties oftestosterone, exhibiting stimulatory action on the development of male sex organs and secondary sex characteristics, although it is not degraded by enzymes in the gastrointestinaltract, and therefore it can only be taken orally View more+

Request For Quotation

1. Names and Identifiers

: 1.1 Name; 17-Methyltestosterone; 1.2 Synonyms; (17Β)-17-Hydroxy-17-methylandrost-4-en-3-one (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-on (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one 17-Methyltestosteron 17α-Methyl-3-oxo-4-androsten-17Β-ol 17α-Methyltestosterone Android Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17Β)- Androst-4-en-3-one, 17Β-hydroxy-17-methyl- Dumogran EINECS 200-366-3 Hormale Malogen Masenone MESTERONE METANDREN METHYL TESTOSTERONE methyltestosterone methyl-testosterone Metrone MFCD00003655 mtmucorettes Neo-Hombreol-M Neo-Homobreol (M) NSC-9701 Nu-man Oraviron ORETON METHYL Syndren Testbormona Testora Testosterone, 17-methyl- Testred; View all

1.3 CAS No.: 58-18-4

1.4 CID: 6010

1.5 EINECS(EC#): 200-366-3

1.6 Molecular Formula: C20H30O2 (isomer)

1.7 Inchi: InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1

1.8 InChIkey: GCKMFJBGXUYNAG-HLXURNFRSA-N

1.9 Canonical Smiles: CC12CCC(=O)C=C1CCC3C2CCC4(C3CCC4(C)O)C

1.10 Isomers Smiles: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C

2. Properties

2.1 Density: 1.0434 (rough estimate)

2.1 Melting point: 162-168 °C(lit.)

2.1 Boiling point: 383.47°C (rough estimate)

2.1 Refractive index: 1.4800 (estimate)

2.1 Flash Point: 5 °C

2.1 Precise Quality: 302.22500

2.1 PSA: 37.30000

2.1 logP: 4.26930

2.1 Solubility: H2O: ≤0.5 mg/mL

2.2 AnalyticLaboratory Methods: Analyte: methyltestosterone;; matrix: chemical identification; procedure: infrared absorption spectrophotometry with comparison to standards

2.3 Appearance: White to Off-White Crystalline Powder

2.4 Chemical Properties: white to slightly yellowish-white crystalline

2.5 Color/Form: white

2.6 Odor: Odorless

2.7 Physical: Solid

2.8 pKa: 15.13±0.60(Predicted)

2.9 Water Solubility: Practically Insoluble

2.10 Spectral Properties: Specific optical rotation: +69 to +75 deg at 25 deg C/D (dioxane)
MAX ABSORPTION (97% SULFUR): 298 NM (LOG E= 4.26); 497 NM (LOG E= 2.86)
IR: 5051 (Coblentz Society Spectral Collection)
UV: 4-837 (Organic Electronic Spectral Data, Phillips et al, John Wiley & Sons, New York)
MASS: 64978 (NIST/EPA/MSDC Mass Spectral Data Base, 1990 Version)

2.11 Stability: Stable under normal temperatures and pressures.

2.12 StorageTemp: 2-8°C

3. Use and Manufacturing

3.1 Definition: ChEBI: A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.

3.2 GHS Classification: Signal: Danger
GHS Hazard Statements
Aggregated GHS information provided by 37 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

H302+H312+H332 (29.73%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]
H302 (29.73%): Harmful if swallowed [Warning Acute toxicity, oral]
H312 (29.73%): Harmful in contact with skin [Warning Acute toxicity, dermal]
H332 (29.73%): Harmful if inhaled [Warning Acute toxicity, inhalation]
H350 (64.86%): May cause cancer [Danger Carcinogenicity]
H351 (29.73%): Suspected of causing cancer [Warning Carcinogenicity]
H360 (32.43%): May damage fertility or the unborn child [Danger Reproductive toxicity]
H361 (67.57%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

Precautionary Statement Codes
P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P330, P363, P405, and P501; View all

3.3 Methods of Manufacturing: Prepared from 17-methyl-delta5,6-androstene-3,17-diol

3.4 Purification Methods: This anabolic steroid is crystallised from hexane or hexane/*benzene. It has E1cm 1% 495-530 at 241nm (EtOH). The colour reaction with 2,4-dinitrophenyl hydrazine is used for assaying it. [Gornall & Macdonald J Biol Chem 201 279 1953.] In another colour reaction the sterone (1mg) in acetic acid (0.2ml) + 88% H3PO4 (2mL) is allowed to stand for 1hour when it becames fluorescent. After 1hour it is diluted with acetic acid (~3mL) and provides a strong yellow fluorescence with the intensity of 50-100 times that of estrone. [Stuart & Stuckey J Pharm Pharmacol 1 130 1949, Openauer Rec Trav Chim Pays-Bas 56 137 137, Beilstein 8 IV 1010.] 17-Methyltestosterone Preparation Products And Raw materials Raw materials

3.5 Usage: Androgen. It has been used as an androgenic agent. Controlled substance (anabolic steroid).

4. Safety and Handling

4.1 Symbol: GHS08

4.1 Hazard Codes: F,T,Xi,Xn

4.1 Signal Word: Danger

4.1 Risk Statements: 45-63-22-20-19-11-61-60-36/37/38-38-10

4.1 Safety Statements: 53-36/37-45-24/25-22

4.1 Exposure Standards and Regulations: The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl methyltestosterone, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
Schedules of controlled substances are established by section 202 of the Controlled Substances Act (21 U.S.C. 812). Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation. DEA Code #: 4000; Drug class: anabolic steroids.

4.2 Packing Group: III

4.2 Octanol/Water Partition Coefficient: log Kow = 3.36

4.3 Hazard Class: 6.1(b)

4.3 Hazard Declaration: H350-H361

4.3 DisposalMethods: SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

4.4 RIDADR: 3249

4.4 Safety Profile: Poison byintraperitoneal route. Moderately toxic byingestion. Human teratogenic effects byingestion: developmental abnormalities ofthe urogenital system. Experimentalteratogenic and reproductive effects. Humansystemic effects: cholestatic jaundce, weightloss or decreased weight gain. Questionable human carcinogen producing liver tumors.A synthetic androgenic steroid. Whenheated to decomposition it emits acridsmoke and irritating fumes.

4.5 Caution Statement: P201-P280-P308 + P313

4.5 Formulations/Preparations: Oral: Capsules: 10 mg Android (C-III), (Valeant); Testred (C-III), (Valeant); Virilon (C-III), (Star). Oral: Tablets: 10 mg Methitest, (Global), 25 mg Methitest, (Global).
Grade: NF
USP, BP, micronized grades

4.6 WGK Germany: 3

4.6 RTECS: BV8400000

4.6 Safety: Hazard Codes:T,Xn,Xi ,F
Risk Statements: 45-63-22-20-19-11-61-60-36/37/38
R45:May cause cancer.
R63:Possible risk of harm to the unborn child.
R22:Harmful if swallowed.
R20:Harmful by inhalation.
R19:May form explosive peroxides.
R11:Highly flammable.
R60:May impair fertility.
R61:May cause harm to the unborn child.
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 53-36/37-45-24/25-22
S53:Avoid exposure - obtain special instructions before use.
S36/37:Wear suitable protective clothing and gloves.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S24/25:Avoid contact with skin and eyes.
S22:Do not breathe dust.
RIDADR: 3249
WGK Germany: 3
RTECS: BV8400000
HazardClass: 6.1(b)
PackingGroup: III

4.7 Specification: Methyltestosterone (CAS NO. 58-18-4), its Synonyms are (17-beta)-17-Hydroxy-17-methylandrost-4-en-3-one ; 17(alpha)-Methyl-delta4-androsten-17(beta)-ol-3-one ; 17-Hydroxy-17-methyl-3-keto-androstene-4 ; 17-beta-Hydroxy-17-methylandrost-4-en-3-one ; 17alpha-Methyl-3-oxo-4-androsten-17beta-ol ; 17alpha-Methyl-delta-androsten-17beta-ol-3-one ; M.T.Mucorettes ; Malestrone ; Androst-4-en-3-one, 17-beta-hydroxy-17-methyl- ; Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17beta)- ; Androst-4-en-3-one, 17beta-hydroxy-17-methyl- .

4.8 Toxicity

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	TDLo	oral	39mg/kg/33W-I (39mg/kg)	LIVER: "JAUNDICE, CHOLESTATIC"	American Journal of Gastroenterology. Vol. 82, Pg. 461, 1987.
mouse	LD50	intraperitoneal	400mg/kg (400mg/kg)		Drugs in Japan Vol. 6, Pg. 830, 1982.
mouse	LD50	oral	1860mg/kg (1860mg/kg)		Drugs in Japan Vol. 6, Pg. 830, 1982.
mouse	LD50	subcutaneous	> 5gm/kg (5000mg/kg)		Drugs in Japan Vol. 6, Pg. 830, 1982.
rat	LD50	intraperitoneal	1050mg/kg (1050mg/kg)		Drugs in Japan Vol. 6, Pg. 830, 1982.
rat	LD50	oral	2500mg/kg (2500mg/kg)		Drugs in Japan Vol. 6, Pg. 830, 1982.
rat	LD50	subcutaneous	5gm/kg (5000mg/kg)		Drugs in Japan Vol. 6, Pg. 830, 1982.

View all

5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Carcinogenicity, Category 1B

Reproductive toxicity, Category 2

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Danger
Hazard statement(s)	H350 May cause cancer H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s)
Prevention	P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/protective clothing/eye protection/face protection.
Response	P308+P313 IF exposed or concerned: Get medical advice/ attention.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

6. NMR Spectrum

13C NMR : in CDCl3

1H NMR : 400 MHz in CDCl3

IR : KBr disc

IR : nujol mull

Mass

Mass spectrum (electron ionization)

7. Synthesis Route

58-18-4Total: 2 Synthesis Route

57-83-0 489 Suppliers

1096-38-4 54 Suppliers

58-18-4 404 Suppliers

145-13-1 365 Suppliers

64-85-7 50 Suppliers

17398-60-6

30802-24-5

7350-00-7 2 Suppliers

Literatures:
Steroids, , vol. 73, # 14 p. 1465 - 1474
Yield: null

143579-42-4

1971-59-1

58-18-4 404 Suppliers

Literatures:
Bi, Honggang; Masse, Robert; Just, George Steroids, 1992 , vol. 57, # 7 p. 306 - 312
Yield: ~0%

8. Other Information

8.0 Merck: 13,6148

8.1 BRN: 2057425

8.2 Overview: 17-Methyltestosterone, a synthetic derivative of testosterone, is an androgen and anabolic steroid (AAS) medication. It is mainly used in the treatment of low testosterone levels in men, delayed puberty in boys, at low doses as a component of menopausal hormone therapy for menopausal symptoms like hot flashes, osteoporosis, and low sexual desire in women, and to treat breast cancer in women (1-3). It appears as white or creamy white crystals or powder, which is soluble in various organic sol vents but is practically insoluble in water. It should be subject to oral administration.
Methyltestosterone was first discovered in 1935 and was introduced for medical use in 1936. It was synthesized shortly after the discovery of testosterone, being one of the first synthetic AAS drug. 17-Methyltestosterone, beyond its medical function, can also be used to improve physique and performance, although it is not as commonly used as other AAS for such purposes due to its androgenic effects, estrogenic effects, and risk of liver damage. The drug is a controlled substance in many countries and so non-medical use is generally illicit.; View all

8.3 Indication and administration: It has been used in the treatment of various symptoms such as hypogonadism, cryptorchidism, delayed puberty, and erectile dysfunction in males, and in low doses to treat menopausal symptoms (specifically for osteoporosis, hot flashes, and to increase libido and energy), postpartum breast pain and engorgement.
In US, 17-Methyltestosterone is an anabolic steroid hormone that majorly used to treat men with a testosterone deficiency, hypogonadism and delayed puberty. Hypogonadism include both primary type and hypogonadotropic type: the former one can be caused by cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. The later one includes idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause. It has also been used in combination with esterified estrogens for the treatment of moderate to severe vasomotor symptoms associated with menopause in females.
17-Methyltestosterone is administered orally. The suggested dosage varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patient's response and the appearance of adverse reactions. Replacement therapy in androgen-deficient males usually demands 10 to 50 mg of 17-Methyltestosterone daily. However, the chronological and skeletal ages must be taken into consideration both in determining the initial dose and in adjusting the dose. Doses used in the treatment of the delayed puberty generally are in the lower range of that given above, and for a limited duration, for example 4 to 6 months. For the treatment of women breast cancer, the dosage of 17-Methyltestosterone in females is from 50-200 mg daily.; View all

8.4 Mode of action: 17-Methyltestosterone take effects through two main mechanisms: activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors.
17-Methyltestosterone can enter into the target tissue cells, binding to the androgen receptor, or being reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly, yielding a even stronger androgenic potency. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA, which is called hormone response elements (HREs). This process regulates the transcriptional activity of various genes, further producing the androgen effects.

8.5 Adverse reactions: 17-methyltestosterone can cause various kinds of adverse reactions. Common side effects include increased facial/body hair growth, scalp hair loss, increased aggressiveness, skin, acne, seborrhea, and sex drive and spontaneous erections. There are also some kinds of estrogenic side effects such as breast tenderness, gynecomastia, fluid retention, and edema. Men can suffer hypogonadism, testicular atrophy, and reversible infertility. Women can sometimes suffer partially irreversible virilization including clitoromegaly, breast atrophy, voice deepening, hirsutism and muscle hypertrophy, as well as menstrual disturbances and reversible infertility.
17-methyltestosterone may also cause hepatotoxicity including elevated liver enzymes, cholestatic jaundice, peliosis hepatis, hepatomas, and hepatocellular carcinoma. It can also have adverse effect on the cardiovascular system such as causing erythropoiesis, increase hematocrit levels or even polycythemia, further leading to even thrombic events such as embolism and stroke. Finally, long-term treatment increase the risk of cancer. Some extreme cases also include hypomania/mania, depression, delusions, suicidality and psychosis.; View all

8.6 Warning and precaution: People of the following cases should not use it: allergy; prostate cancer; male breast cancer, pregnant.
People with liver or kidney disease, an enlarged prostate, heart disease, congestive heart failure should use with caution.

8.7 References

Alexandre Hohl (6 April 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 204–. ISBN 978-3-319-46086-4.
Shahidi NT (2001). "A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids". Clin Ther. 23 (9): 1355–90.
Shi, Y., et al. "Molecular identification of an androgen receptor and its changes in mRNA levels during 17α-methyltestosterone-induced sex reversal in the orange-spotted grouper Epinephelus coioides. " Comp Biochem Physiol B Biochem Mol Biol 163.1(2012):43-50.
Zheng, Z., B. A. Armfield, and M. J. Cohn. "Timing of androgen receptor disruption and estrogen exposure underlies a spectrum of congenital penile anomalies." PNAS 112.52(2015):201515981.
Komada, S., et al. "Side gland of Suncus murinus, as a new model of sebaceous gland: 5α-reductase, androgen receptor, and nuclear androgen content in male and female animals." Archives of Dermatological Research 280.8(1989):487-493.
Kicman, A T (2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521.
Jeffrey K. Aronson (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 141–. ISBN 978-0-08-093292-7.
Benjamin J. Sadock; Virginia A. Sadock (26 December 2011). Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Lippincott Williams & Wilkins. ISBN 978-1-4511-7861-6.
Bird, D. R., and K. D. Vowles. "Liver damage from long-term methyltestosterone. " Inpharma 310.8032(1977):261-263.

View all

8.8 Description: Methyltestosterone is a synthetic analog of testosterone that possesses all of the properties of testosterone, exhibiting stimulatory action on the development of male sex organs and secondary sex characteristics, although it is not degraded by enzymes in the gastrointestinal tract, and therefore it can only be taken orally

8.9 Chemical Properties: white to slightly yellowish-white crystalline

8.10 Originator: Metandren ,Ciba,US,1941

8.11 Uses: Androgen. It has been used as an androgenic agent. Controlled substance (anabolic steroid).

8.12 Uses: It is used for the same indications as testosterone for sexual underdevelopment, functional problems of the reproductive system, and the vascular nerve disorders associated with climacteric problems in men. It is also used for dysfunctional uterine bleeding in premenopausal and menopausal women as well as for breast and ovarian cancer.

8.13 Definition: ChEBI: A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.

8.14 Manufacturing Process: 0.6 g of 17-Methyl-?5,6-androstenediol-(3,17) is heated under reflux cooling during 20 hours in 50 cm3 of benzene and 12 cm3 of acetone with 3 g of tertiary chloromagnesium butylate, which may be prepared by conversion of acetone with methyl magnesium chloride. The magnesium is then removed by shaking out with dilute H2SO4; the benzene layer is washed with water, dried with sodium sulfate and then evaporated to dryness. Methyltestosterone (MP 160° to 162°C) is obtained in a yield of more than 75% of the theory, according to US Patent 2,384,335.

8.15 Brand name: Android (Valeant);Metandren (Novartis); Oreton (Schering); Testred (Valeant); Virilon (Star).

8.16 Therapeutic Function: Androgen

8.17 Pharmacokinetics: The synthesis of 17α-methyltestosterone made available a compound that was orally active in daily doses between 10 and 50 mg, which is equivalent to a 400 mg oral dose of testosterone. The presence of a 17α alkyl group reduces susceptibility to hepatic oxidative metabolism, thereby increasing oral bioavailability by slowing metabolism. Following oral administration, methyltestosterone is well absorbed from the gastrointestinal tract, with a half-life of approximately 3 hours. This drug has the androgenic and anabolic activities of testosterone. Although orally active, it is more effective when administered sublingually. The alkylated oral androgens should be viewed as potentially hepatotoxic and should not be used.

8.18 Safety Profile: Poison by intraperitoneal route. Moderately toxic by ingestion. Human teratogenic effects by ingestion: developmental abnormalities of the urogenital system. Experimental teratogenic and reproductive effects. Human systemic effects: cholestatic jaundce, weight loss or decreased weight gain. Questionable human carcinogen producing liver tumors. A synthetic androgenic steroid. When heated to decomposition it emits acrid smoke and irritating fumes.

8.19 Chemical Synthesis: Methyltestosterone, 17β-hydroxy-17α-methylandrost-4-en-3-one (29.1.7), is also synthesized from androstenolone by reacting it with methylmagnesiumiodide, forming the corresponding tertiary alcohol (29.1.6), and subsequent oxidation of the hydroxyl group at C3 to a ketone using chromium (VI) oxide. Simultaneous isomerization of the double bond takes place under the reaction conditions, giving the desired methyltestosterone (29.1.7).

8.20 Purification Methods: This anabolic steroid is crystallised from hexane or hexane/*benzene. It has E1cm 1% 495-530 at 241nm (EtOH). The colour reaction with 2,4-dinitrophenyl hydrazine is used for assaying it. [Gornall & Macdonald J Biol Chem 201 279 1953.] In another colour reaction the sterone (1mg) in acetic acid (0.2ml) + 88% H3PO4 (2mL) is allowed to stand for 1hour when it becames fluorescent. After 1hour it is diluted with acetic acid (~3mL) and provides a strong yellow fluorescence with the intensity of 50-100 times that of estrone. [Stuart & Stuckey J Pharm Pharmacol 1 130 1949, Openauer Rec Trav Chim Pays-Bas 56 137 137, Beilstein 8 IV 1010.]

9. Computational chemical data

Molecular Weight: 302.45g/mol
Molecular Formula: C₂₀H₃₀O₂
Compound Is Canonicalized: True
XLogP3-AA: null
Exact Mass: 302.224580195
Monoisotopic Mass: 302.224580195
Complexity: 550
Rotatable Bond Count: 0
Hydrogen Bond Donor Count: 1
Hydrogen Bond Acceptor Count: 2
Topological Polar Surface Area: 37.3
Heavy Atom Count: 22
Defined Atom Stereocenter Count: 6
Undefined Atom Stereocenter Count: 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Isotope Atom Count: 0
Covalently-Bonded Unit Count: 1
CACTVS Substructure Key Fingerprint: AAADceB4MAAAAAAAAAAAAAAAAAAAAYAAAAAwYIAAAAAAAGDAAAAAGgAACAAAD0SAgAACAAAAAgCIAqBSAAAAAAAgAAAACAEAAEgAABIAAQAAQAAEgAAIAQOIyPCPgAAAAAAAAACAAAQAACAAAYAADAAAAA==

10. Question & Answer

What are the Synthesis and Chemical Reactions of 17-Methyltestosterone? Jul 03 2023
General Description 17-Methyltestosterone is a synthetic derivative of testosterone used in healthcare steroid manufacturing. It is produced from natural products like diosgenin through a series of ch..
How to Synthesize 17-Methyltestosterone? Oct 30 2022
Background Technology 17-Methyltestosterone, as a androgenic drug, is clinically used to promote the development and maintenance of male sexual organs and secondary sexual characteristics, as well as ..
What are the indications for 17-Methyltestosterone tablets? Mar 08 2022
17-Methyltestosterone tablets belong to a natural androgen hormone commonly used in hormone replacement therapy. It has excellent therapeutic effects, but its duration of action is relatively short, r..
What is Methyltestosterone (17-Methyltestosterone) and How Does it Work? Sep 14 2021
Methyltestosterone (17-Methyltestosterone), also known as 17b-hydroxy-17a-methylandrost-4-en-3-one, is a hormone steroid drug developed by the former Ciba company in Switzerland. It has been widely ma..

11. Recommended Suppliers

Global350SuppliersView all >>

Anhui Ruihan Technology Co.,Ltd Diamond member

1YR

Products:Chemical;Pharmaceutical Raw Materials
Tel:00-86-19314086586
Email:daisy@anhuiruihan.com

Top Grade 17-Methyltestosterone CAS 58-18-4 with Wholesale Price

Purity:99%Packing: 200kg/bag FOB
Price: 50 USD/kg
Time: 2023/10/03

Inquire

Shanghai Xinlijie New Materials Co.,Ltd. Diamond member

1YR

Products:Pharmaceutical Intermediate , Apis , Food Additives , Herbal Extracts , Fine Chemicals , ...
Tel:00-86-13167237119
Email:anne@xljxcl.com

CAS 58-18-4 17-Methyltestosterone high quality and sample acceptable

Purity:99%Packing: 200kg/bag FOB
Price: 100 USD/kilogram
Time: 2023/10/03

Inquire

Hebei Chengcai Biotechnology Co., LTD Diamond member

1YR

Products:We are engaged in the development, marketing and sales of apis, intermediates, natural products (extracts), fine chemicals, food additives, agricultural chemicals and other products.
Tel:0086-0319-19133539026
Email:ZHANGZHANG@chengcaibio.com

Factory supply 17-Methyltestosterone CAS 58-18-4

Purity:99%Packing: 200kg/bag FOB
Price: 10 USD/kg
Time: 2023/10/03

Inquire

Hebei Ruiyao Biotechnology Co., Ltd Diamond member

2YRS

Products:Cosmetic Grade Chemical Raw Materical,Chemicals Raw Materials,API,Pharmaceutical Intermediates,Organic Chemicals
Tel:0311-88180881-19932787653
Email:sale06@ruiyaobio.com

99% purity high quality powder Cas 58-18-4 17-Methyltestosterone

Purity:99%Packing: 200kg/bag FOB
Price: 30 USD/kg
Time: 2023/09/28

Inquire

Wuhan Puhe Technology Co. LTD Diamond member

1YR

Products:chemical raw materical
Tel:+86-0311-+8615130076781
Email:Nancy@wuhanphe.com

methyltestosterone ,CAS NO.:58-18-4 Factory direct sales,100% customs clearance

Purity:99%Packing: 200kg/bag FOB
Price: 100 USD/mt
Time: 2023/09/28

Inquire

12. Realated Product Infomation

67-81-2 METHYLTESTOSTERONE

Recently Updated : 100068-18-6 1932530-95-4 1379444-92-4 186893-71-0 1933714-75-0 98291-26-0 310456-63-4 355824-69-0 1932187-58-0 664975-71-7